

February 27<sup>th</sup>, 2025



#### Disclaimer

This document has been prepared by Puig Brands, S.A. (the "Company" and together with its subsidiaries, the "Group") for the sole purpose expressed herein and neither this document nor the information contained herein, can be used, disclosed, or published by third parties for other purposes without the prior written consent of the Company.

Neither the Company, nor other companies of the Group, will assume any responsibility, whether for negligence or other reason, for any damage or loss arising from any use of this document or the information contained therein. In particular, no investment decision on the Company's shares, securities or other financial instruments of the Company linked to them shall be taken on the basis of this documents and the information contained herein.

This document and the information contained herein should not be interpreted as an offer or invitation to acquire, subscribe, buy, sell, or exchange shares or securities of the Company or financial instruments referenced to or which underlying is shares or securities of the Company. It should also not be considered a solicitation of an offer for such activities, nor a recommendation or advice regarding shares or securities issued by the Company or financial instruments referenced to or which underlying is shares or securities of the Company. It should also not be considered a solicitation of an offer for such activities, nor a recommendation or advice regarding shares or securities issued by the Company or financial instruments referenced to or which underlying is shares or securities of the Company.

The securities of the Company have not been registered under the United States Securities Act of 1933, and cannot be or will not be offered or sold in the United States, except in compliance with an effective registration statement or under a valid exemption from registration requirements. Likewise, these securities cannot be offered or sold in other jurisdictions except in compliance with applicable laws and regulations of those jurisdictions.

#### Forward-Looking Statements

The information in this document may include forward-looking statements, which are based on current expectations, projections and assumptions about future events. These forward-looking statements include all matters that are not historical facts. The words "believe", "expect", "anticipate", "intends", "estimate", "forecast", "project", "plan", "will", "may", "should", "target", and similar expressions identify forward-looking statements. These forward-looking statements. These forward-looking statements, as well as those included in any other information discussed in this document, are subject to known or unknown risks, uncertainties and assumptions about the Group and its operations, including, among other things, the development of its business, its growth plan and targets, trends in its industry, economic and demographic trends, and the Group's future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions which may be beyond the Group's control, the events in the forward-looking statements may not occur and actual results, performance or achievements may materially differ from any future results, performance or achievements that may be expressed or implied in this document. No representation or warranty is made that any forward-looking statement will come to pass. Forward-looking statements speak as of the date of this document, whether as a result of new information, future events or otherwise. None of the Company or any of the Group, or any of their respective directors, officers, employees, advisers or agents, accepts any responsibility or liability whatsoever or makes any representation or warranty, expressed or implied, as to the truthfulness, fairness, accuracy, completeness to reflect events or circumstances occurring after the date of this document.

Alternative Performance Measures and Non-IFRS Information

This document includes financial information prepared by the Company under the International Financial Reporting Standards ("IFRS") adopted by the European Union, as well as certain non-IFRS consolidated financial measures of the Group derived from (or based on) its accounting records, and which it regards as alternative performance measures ("APMs") for the purposes of Commission Delegated Regulation (EU) 2019/979 of March 14, 2019 and as defined in the European Securities and Market Authority Guidelines ("ESMA") on Alternative Performance Measures dated October 5, 2015. Other companies may calculate such financial information differently or may use such measures for different purposes than the Company does, limiting the usefulness of such measures as comparative measures. These measures should not be considered as alternatives to measures derived in accordance with IFRS, have limited use as analytical tools, should not be considered in isolation and, may not be indicative of the Company's results of operations. Recipients should not place undue reliance on this information.



**01** 02 03

#### ► ◆ FY 2024 results by Marc Puig, Chairman & CEO Financial review by Joan Albiol, CFO Outlook



# **Puig** A home of love brands, within a family company, that furthers wellness, confidence and self-expression, while leaving a better world





FY 2024 Key Highlights	Net Revenue FY 2024	<b>€ 4,790m</b> Net Revenue	<b>11.3%</b> Reported Net Revenue Growth	<b>10.9%</b> LFL Net Revenue Growth
	Gross Profit margin FY 2024	<b>€ 3,588m</b> Gross Profit	<b>74.9%</b> Gross Profit Margin	
	Adj. EBITDA FY 2024	<b>€ 969m</b> Adj. EBITDA (€823m Reported EBITDA)	<b>20.2%</b> Adj. EBITDA Margin	
	Adj. Net Profit FY 2024	<b>€ 551m</b> Adj. Net Profit (€531m Reported Net Profit)	<b>11.5%</b> Adj. Net Profit Margin (11.1% Reported Net Profit Margin)	<b>€ 1.02</b> Adj. EPS <sup>1</sup>
	Cash Flow and Leverage	<b>65%</b> FCF Conversion (as a % of Adjusted EBITDA)	<b>1.1x</b> Leverage (Net Debt/Adjusted EBITDA)	



### **FY 2024 Net Revenues** 10.9% like-for-like growth in 2024

FY24 growth



#### Key drivers:

- •• Double-digit growth in Fragrance and Fashion
  - Continued outperformance of Prestige complemented by strong growth in Niche
- •• Makeup posted a low single-digit negative performance for the year
  - This was a result of specific sell-in / sell-out dynamics further impacted by the voluntary withdrawal of the Airbrush Flawless Setting Spray
- •• Continued diversification into Skincare with strong organic growth in dermo-cosmetics and the incorporation of Dr. Barbara Sturm
- •• Positive impact on LFL growth due to a hyperinflation adjustment of the Argentine Peso

Growth in 2024 was weighted towards the second half



2024 - Evolution of quarterly like-for-like growth





FY 2024 Net Revenues by business segment



Fragrance & Fashion

+13.6%

Reported and constant perimeter growth

#### €3,538m

Net Revenues 73% Total<sup>1</sup>



Makeup

(1.3%) Reported and constant perimeter growth

€763m

Net Revenues 16% Total<sup>1</sup>



#### Skincare

+19.8% +7.4% Reported Constant growth growth

Constant perimeter growth

€ 516m

Net Revenues 11% Total<sup>1</sup>





Continued core execution strength in Fragrances & Fashion Double-digit growth in FY24 with three brands in the top 10 rankings worldwide

FY 2024 Fragrance Value Market Share<sup>1</sup>

11.5% Global Value Market Share Three brands within the top 10 rankings<sup>1</sup> worldwide of selective fragrance brands

#5	rabanne	
#6	CAROLINA HERRERA	Top 10 since 2020
#8	Jean Paul GAULTTER	Top 10 since 2024



Good Girl is the No.1 fragrance franchise globally. Three out of the top 5 fragrance lines in masculine and feminine rankings



Carolina Herrera's Good Girl achieves #1<sup>1</sup> position as feminine fragrance line in the US and worldwide in 2024



Jean Paul Gaultier is Puig's fastest-growing brand and Le Male reaches #3<sup>1</sup> masculine fragrance line worldwide in 2024



Puig's €1bn brand, Rabanne's One Million was the #4<sup>1</sup> masculine fragrance line worldwide; launched Million Gold for Her and Him in 2024

### Makeup Challenging year for growth



Maintained and strengthened leading market positions in spite of challenges

#### #1

Charlotte Tilbury Prestige Makeup brand UK

#### #3

Charlotte Tilbury Prestige Makeup brand US (vs. #5 in 2023)





Early days of building the Makeup proposition for core Fragrance and Fashion led Brands



Gaps in the sell-in and sell-out, along with the impact of dupes and the withdrawal of the Airbrush Flawless Setting spray slowed growth

#### Skincare Leveraging multiple streams of growth



Fastest growing category in 2024 with diversified offerings







Steady growth in derma with Uriage delivering double-digit growth



The addition of niche skincare brand Dr. Barbara Sturm – adds ultra prestige skincare to Puig's offering. Integration was also completed in 2024.



FY 2024 Net Revenues by Geography

EMEA 55% <sup>1</sup> of total	<b>€ 2,620m</b> Net Revenues	+12.8% Reported growth	+11.6% Constant perimeter growth
Americas 36% <sup>1</sup> of total	<b>€ 1,715m</b> Net Revenues	<b>+11.1%</b> Reported growth	<b>+9.5%</b> Constant perimeter growth
APAC 10% <sup>1</sup> of total	<b>€ 455m</b> Net Revenues	<b>+3.7%</b> Reported and constant perimeter growth	



### **ESG highlights** Embedded in Puig values and long-term vision

The Puig commitment to sustainability goes beyond legal requirements, contributing globally to two ambitious sustainability goals:

Helping limit global warming to 1.5 °C by 2030 Becoming a net zero organization by 2050

The strategy of Puig and its brands are aligned with the most recognized international commitments, standards, certifications, ratings and initiatives.









# ► ◆ Financial review by Joan Albiol, CFO Outlook

Income Statement Overview

n€m	FY 2023	FY 2024	% YoY Growth
Net Revenues	4,304	4,790	+11.39
Cost of Sales	(1,089)	(1,202)	
Gross Profit	3,215	3,588	+11.6%
Gross Margin (%)	74.7%	74.9%	
Distribution expenses	(218)	(220)	
Advertising and promotion expenses	(1,338)	(1,551)	
Selling, general and administrative expenses	(966)	(1,058)	
Operating Profit	693	759	+9.5%
Operating Margin (%)	16.1%	15.8%	
Other Operational Income / (Expenses)	(14)	(147)	
Financial Result	(87)	19	
Results from Associates and JV	51	61	
Profit Before Tax	643	693	
ncome Tax	(143)	(150)	
Effective tax rate (%)	22.3%	21.7%	
Net Profit	500	543	
Non-controlling Interests	(35)	(12)	
Net Profit attributable to the parent company	465	531	
Adjusted EBITDA	863	969	+12.39
Adjusted EBITDA Margin (%)	20.0%	20.2%	
Adjusted Net Profit	478	551	+15.5%
Adjusted Net Profit Margin (%)	11.1%	11.5%	



### Adjusted EBITDA Margin Evolution



+0.2ppt improvement in Adjusted EBITDA vs. FY 2023 was driven by several impacts

Steady Gross Margin performance with an increase of +0.2ppt vs. FY 2023 driven by **continued premiumization and increased desirability of our brands** coupled with **efficient cost management and operating leverage** partially offset by a higher level of inventory losses in 2024 versus 2023.

Our c.75% Gross Margin is at a market leading level in the Premium Beauty industry, and is the result of continued investment in our brands Distribution costs improved by +0.5ppt vs. FY 2023 due to the effect of **continued optimisation and normalisation versus early 2023 levels** 

A&P remained in line with levels deployed in recent years, allowing for **continued investment into our brands**. 2024 A&P was 1.3ppt higher than 2023.

0.4ppt improvement in SG&A driven by **operating leverage** 

D&A increase of +0.5ppt vs FY 2023 as a percentage of Net Revenues is a **result** of increased investment in capex in recent years



### FY 2024 Operating Profit by Category





0.3ppt decrease in Operating Margins. FY 2023 driven by an **increase in A&P and the dilutive effect of smaller brands and offerings** within the Puig portfolio which require investment to scale

Fragrance, the largest and most profitable category, saw operating margin improvement driven by a strong performance and increased operating leverage during the second half of 2024. Makeup operating margin has been impacted by:

- The smaller scale of the makeup exercises of some of our fragrance-led brands which are in their early stages of growth
- Voluntary withdrawal of the Airbrush Flawless Setting Spray had a small impact on the profitability of the Charlotte Tilbury brand, which otherwise remained strong

Skincare is still scaling and expected to benefit from operating leverage as more of the recent acquisitions grow to scale, and with the completion of the integration of Dr. Barbara Sturm (which had a marginal dilutive impact as expected)



#### FY 2024 Adjusted Net Profit Evolution

Operating Profit to Net Profit Attributable to Puig

In€m	FY 2023	FY 2024	% YoY Growth
Operating Profit	693	759	9.5%
Operating Margin (%)	16.1%	15.8%	
Other Operational Income / (Expenses)	(14)	(147)	
Financial Result	(87)	19	
Results from Associates and JV	51	61	
Profit before Tax	643	693	7.7%
Income Tax	(143)	(150)	
Net Profit	500	543	8.5%
Non-controlling Interests	(35)	(12)	
Net Profit attributable to the parent company	465	531	14.1%
Adjusted Net Profit to Puig	478	551	15.5%
Adjusted Net Profit Margin (%)	11.1%	11.5%	

**Reported Net Profit to Puig grew 14.1% to reach €531 million** as a result of:

- Positive impact from operating profit improvement
- Improved financial result
  - Income generated from the reassessment of future obligations related to the acquisitions of Charlotte Tilbury and Byredo
  - \_ A smaller negative impact from the Argentina FX impact
  - Counterbalanced by an Increased financing expenses during 1H 2024
- Reduction of Non-controlling interests due to the acquisition of minority stakes over the course of 2024
- Lower tax rate than anticipated
- These factors were offset by increased Other operating expenses impacted by IPO costs, M&A expenses and other costs, the largest of which was an extraordinary award given to all Puig employees at IPO amounting in total to €94m in cash bonuses

Adjusted for non-recurring items, Adjusted Net Profit to Puig saw strong +15.5% growth with +0.4ppt improvement vs. FY 2023 with a margin of 11.5%



#### Overview of FY 2024 Cash Flow Statement

Cash Flow from Operations

In€m	FY 2023	FY 2024
Net Profit attributable to the Parent Company	465	531
Cashflow adjustments	286	168
Cashflow non-recurring Items	6	85
Change in Working Capital	(194)	41
Adjusted Operating Cash Flow	563	825
Сарех	(178)	(191)
% Net Revenues	(4.1)%	(4.0)%
Free Cash Flow from Operations	385	634
% Adjusted EBITDA	45%	65%
Cashflow non-recurring Items	(6)	(85)
Operational Cash Flow	379	549

Free Cash Flow Conversion increased significantly reaching 65% of Adjusted EBITDA

**Significant improvement in working capital** led by inventory optimisation and improved liabilities

management

Capex levels at 4% of Net Revenues aligned with expectations

Operational Cash Flow was impacted by Non-recurrent IPO related cash impacts





### Recap of key events impacting our capital structure in FY 2024



Acquisition of 65% of Dr. Barbara Sturm



Listing on the Spanish stock exchange with Primary component of  ${\bf \in 1.4bn}$ 



Accelerated buyout of all remaining minority stakes in Byredo to 100%



Increase of ownership in Charlotte Tilbury from 55% at the end of 2023 to 78.5% currently. Extension of strategic partnership with Charlotte Tilbury until 2031.



# Leverage stands at $1.1x^1$ as of Dec-24, comfortably below medium-term leverage threshold (below 2.0x)



Note: <sup>1</sup> Leverage ratio corresponds to Net Debt Balance at end of period over Adjusted EBITDA; Adjusted EBITDA for FY23 and FY24 was €863m and €969m respectively



# Our Liabilities from Business Combinations were reduced by c.€1.3bn to €1.1bn net during FY 2024

Evolution of Liabilities from Business Combinations (in  ${\ensuremath{\in}} m)$ 



Liabilities from Business Combinations decreased from €2,385m to €1,088m mostly driven by:

- The incorporation of the put / call liability of Dr. Barbara Sturm
- The accelerated buyout of the financial investor's minority stake in Charlotte Tilbury as well as the entire remaining minority holding of Byredo bringing our ownership to 100% at IPO at attractive terms
- An incremental 5.4% minority interest acquired in Charlotte Tilbury
- All of the actions over the course of FY2024 have increased Puig's ownership in Charlotte Tilbury from 55% to 78.5%

 Periodic reassessment of future obligations related to the future liabilities related to the acquisitions of Charlotte Tilbury, Byredo, Kama Ayurveda and Loto del Sur adjusted for time value and foreign exchange adjustments





Maturity calendar of the €1.1bn Liabilities from Business Combinations over future years







FY 2024 results by Marc Puig, Chairman & CEO Financial review by Joan Albiol, CFO ►•• Outlook



### Reiteration of Financial Outlook for the Medium Term 2025 Outlook

Revenue	High single-digit like-for-like growth, well ahead of the premium beauty market growth	6-8% like-for-like growth expectation reflecting the current state of the beauty market
Adj. EBITDA Margin	Upside potential in the medium-term, allowing for virtuous re- investment in our brands	Adjusted EBITDA improvement expectation similar to 2024
Capital Structure	Adequate balance sheet management aiming at maintaining strategic flexibility and financing future growth, with Net Debt / Adjusted EBITDA ratio not to exceed 2.0x	
Dividends	Intention to maintain ~40% dividend payout ratio out of reported net profit in line with track record First dividend post-IPO to be paid in 2025 in respect of full year 2024	Payment of €212m, subject to AGM approval, corresponding to 2024 performance
M&A Strategy	Highly selective approach to M&A as we continue to evaluate curated opportunities with a strong strategic fit into our portfolio, while maintaining our capital structure targets	





#### A strong launch calendar for 2025



Major Prestige Fragrance launch in H2



Expansion of Niche Fragrance collections

Charlotte Tilbury

Long pipeline in 2025 with a particularly exciting makeup launch

2H 2025



Steady pipeline of skincare launches

2H 2025

Throughout 2025

25

Throughout 2025







### 2024 Net Revenues Quarterly Breakdown

	Business Segments			
In€m	Q1	Q2	Q3	Q4
Fragrance and Fashion	823.2	775.4	935.2	1004.2
Makeup	172.6	161.9	200.6	228.0
Skincare	134.4	121.6	125.5	134.7
Eliminations	(11.8)	(6.1)	(4.3)	(5.2)
	(	Geographical S	egments	
In€m	Q1	Q2	Q3	Q4
EMEA	617.0	536.6	676.1	790.4
The Americas	404.4	409.5	476.7	424.0
Asia-Pacific	97.0	106.7	104.2	147.2

29



### Reconciliation of Non-IFRS Measures

#### Adjusted EBITDA reconciliation

In€m	FY 2023	FY 2024
EBITDA	849	823
Restructuring costs	1	-
Transaction costs	3	18
IPO costs	5	119
Others	4	9
Adjusted EBITDA	863	969

#### Adjusted Net Profit reconciliation

In€m	FY 2023	FY 2024
Net Profit Attributable to Puig	465	531
Other operational income and expenses	14	147
Other finance income and costs	6	(87)
Tax effect on adjusted items	(2)	(37)
Minority interest on adjusted items	(6)	(3)
Adjusted Net Profit Attributable to Puig	478	551





#### Detailed reconciliation of cash adjustments to Net Profit

Cash Flow from Operations

In €m	FY 2023	FY 2024
Net Profit attributable to the Parent Company	465	531
Profit / (loss) attributable to non-controlling interests	35	12
D&A	170	210
(Profit)/Loss from Associates and JV	(51)	(61)
Financial Expenses	54	58
Other Adjustments <sup>1</sup>	78	(52)
Cashflow adjustments	286	168
Cashflow non-recurring Items	6	85
Change in Working Capital	(194)	41
Adjusted Operating Cash Flow	563	825
Сарех	(178)	(191)
% Net Revenues	(4.1)%	(4.0)%
Free Cash Flow from Operations	385	634
% Adjusted EBITDA	45%	65%
Cashflow non-recurring Items	(6)	(85)
Operational Cash Flow	379	549

Note: <sup>1</sup>Includes deferred tax expense / income, other financial income / expenses, other adjustments, capital gains and losses on disposals of assets and other non-current assets and liabilities.

